For this analysis, researchers reported treatment differences among patients who receive once-daily fluticasone furoate/vilanterol 200/25 µg, fluticasone furoate/umeclidinium/vilanterol 200/31.25/25 µg and fluticasone furoate/umeclidinium/vilanterol 200/62.5/25 µg compared with fluticasone furoate/vilanterol 100/25 µg after an ICS/LABA run-in period.ĭoubling the dose of fluticasone furoate to 200 µg and simultaneously adding umeclidinium 31.25 or 62.5 µg resulted in the greatest improvements in trough FEV 1 after 24 weeks of treatment, Huib A. The mean age was 53 years and most were women. The current analysis examined the effect of simultaneously doubling the dose of fluticasone furoate and adding umeclidinium to fluticasone furoate/vilanterol on lung function, exacerbations and symptom control in patients inadequately controlled on inhaled corticosteroid (ICS)/LABA.Ī total of 2,436 patients with inadequately controlled asthma were included and randomly assigned in the intent-to-treat population. Main results of the CAPTAIN study were previously reported and demonstrated improved lung function and numerical reductions in the annualized rate of moderate or severe exacerbations with triple therapy compared with double therapy. The phase 3a, randomized, double-blind, parallel-group CAPTAIN study was conducted to evaluate the safety and efficacy of Trelegy Ellipta compared with double-combination therapy - fluticasone furoate and vilanterol - in patients with inadequately controlled asthma. Single-inhaler triple therapy with fluticasone furoate 100 µg, umeclidinium 62.5 µg and vilanterol 25 µg ( Trelegy Ellipta, GlaxoSmithKline) is approved as a once-daily, single-inhaler treatment for COPD. If you continue to have this issue please contact to Healioĭoubling the inhaled corticosteroid dose and adding umeclidinium to inhaled corticosteroid/long-acting beta agonist in a single-inhaler triple therapy improved outcomes in inadequately controlled asthma, data from the CAPTAIN study show. Triple ICS/LABA/LAMA FDC and dual LABA/LAMA or ICS/LABA FDCs are characterized by specific efficacy/safety profiles in agreement with the level of blood eosinophil count at baseline.ĬOPD ICS LABA LAMA dual bronchodilation network meta-analysis triple therapy.We were unable to process your request. The weighted efficacy/safety profile resulting from SUCRA provided the following ranking in patients with low eosinophil count: ICS/LABA/LAMA>LABA/LAMA≫ICS/LABA whereas in patients with high eosinophil count the ranking was as follows: ICS/LABA/LAMA>LABA/LAMA>ICS/LABA FDC. The treatment ranking was reported via the surface under the cumulative ranking curve analysis (SUCRA).ĭata obtained from 21,909 COPD patients were extracted from the ETHOS, KRONOS, IMPACT, and TRILOGY studies, the only that fulfilled the strict inclusion criteria of this research.

either dual LABA/LAMA or ICS/LABA therapies administered at fixed-dose combination (FDC) via the same inhaler device.Ī network meta-analysis was performed to assess the efficacy/safety impact of triple ICS/LABA/LAMA FDC compared with dual LABA/LAMA and ICS/LBA FDCs administered via the same inhaler device in COPD patients.

The aim of this study was a quantitative synthesis by considering the studies that directly compared triple ICS/LABA/LAMA vs.

In some studies comparing triple with dual combination therapies in COPD there might be a possible effect of inhaler bias resulting from different inhaler devices being used in comparator arms.

Trelegy ics laba lama about